Video

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

Related Videos
Muhammad Bilal Abid, MD, MRCP
M. Patricia Rivera, MD
Andrea Borondy Kitts
Jacob Sands, MD
Sandip Patel, MD
James L. Mulshine, MD
Zev A. Wainberg, MD, of Jonsson Comprehensive Cancer Center
Chris Labaki, MD, of Dana-Farber Cancer Institute
Quoc-Dien Trinh, MD, of Brigham and Women's Hospital
Renold Capocasale, CEO and founder of FlowMetric, and Grant Morgan, PhD, PMP
Related Content
Paul G. Kluetz, MD
May 9th 2023

Decentralization Efforts Could Engage Community Oncologists

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
June 6th 2022

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

Giuseppe A. Palumbo, MD, PhD
March 9th 2023

COVID-19 Vaccine Efficacy Decreases With Ruxolitinib Use in MPNs

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
June 2nd 2022

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

Mili Arora, MD
July 8th 2022

In the Trenches With the Fellows

Carsten Niemann, MD, PhD, of Rigshospitalet
May 29th 2022

Close Monitoring Recommended Despite Reduced Risk of COVID-19 Mortality in CLL